Neural Stem-Like Cell Reprogramming via Msi1 and Ngn2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cell reprogramming and dedifferentiation lack the ability to create stable, potent, and autologous stem cells, particularly neural stem cells, that can safely integrate into damaged tissues without causing teratoma formation or uncontrolled growth, and existing technologies rely on embryonic or induced pluripotent stem cells with limitations such as ethical concerns and immune rejection.
Innovation Solution
A method involving the transient increase of reprogramming agents like Msi1 and Ngn2 polypeptides, combined with histone acetylation and DNA demethylation, to induce stable expression of neural stem cell markers in somatic cells, allowing them to differentiate into Neural Stem-Like Cells (NSLCs) and other stem-like cells, which can be used for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic or induced pluripotent stem cells are used for cell replacement therapy, then the ability to generate various cell types is improved, but the risk of teratoma formation and immune rejection increases
Solution Approach 1:
The invention extracts and applies only the necessary transcription factors (Msi1 and Ngn2) required for neural stem cell differentiation, rather than using full pluripotent stem cells. This selective extraction allows generation of neural stem cells without the harmful potential of teratoma formation associated with pluripotent cells
Solution Approach 2:
The invention uses Msi1 and Ngn2 polypeptides as intermediary agents to mediate the transformation of somatic cells into neural stem cells. These intermediaries provide a controlled pathway for cell reprogramming that avoids the uncontrolled differentiation potential of pluripotent stem cells
2Reliability
If somatic cells are reprogrammed using transient expression of reprogramming agents, then the stability and safety of the reprogrammed cells is improved, but the complexity of the reprogramming process increases
Solution Approach 1:
The invention extracts only the essential reprogramming components (Msi1 and Ngn2 polypeptides) needed for neural stem cell conversion, eliminating unnecessary steps and agents. This focused approach reduces overall process complexity while maintaining reprogramming effectiveness
Solution Approach 2:
The transient expression of Msi1 and Ngn2 triggers endogenous expression of gene regulators that complete the reprogramming process. The cell's own machinery serves the reprogramming function after initial induction, reducing the need for continuous external intervention and simplifying the overall process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the generation of stable, autologous stem-like cells that can safely differentiate into specific cell types, reducing the risk of teratoma formation and immune rejection, and provides a potent and safe source for regenerative therapies.
Implementation Method 1
combined with histone acetylation and DNA demethylation, to induce stable expression of neural stem cell markers in somatic cells
Implementation Method 2
combined with histone acetylation and DNA demethylation, to induce stable expression of neural stem cell markers in somatic cells
Data Source
AI summary
Described herein are reprogrammed cells, and methods for cell dedifferentiation, transformation and eukaryotic cell reprogramming. Also described are cells, cell lines, and tissues that can be transplanted in a patient after steps of in vitro dedifferentiation and in vitro reprogramming. In particular embodiments the cells are Stem-Like Cells (SLCs), including Neural Stem-Like Cells (NSLCs), Cardiac Stem-Like Cells (CSLC), Hematopoietic Stem-Like Cells (HSLC), Pancreatic Progenitor-Like Cells, and Mesendoderm-like Cells. Also described are methods for generating these cells from human somatic cells and other types of cells. Also provided are compositions and methods of using of the cells so generated in human therapy and in other areas.